Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, doing business as Adaptive, is a Seattle-based for-profit biotechnology company that delivers immunosequencing services and minimal residual disease diagnostic testing to the federal government as a prime contractor, competing full-and-open across civilian health research and defense medical agencies without set-aside participation.

Adaptive's federal capability footprint centers on proprietary immunosequencing assays (ImmunoSEQ) and FDA-cleared ClonoSEQ in vitro diagnostic testing for blood cancer detection and monitoring. ImmunoSEQ services quantitatively assess T-cell and B-cell repertoire breadth and complexity in clinical and research samples; ClonoSEQ provides minimal residual disease testing to detect and monitor clonal populations in multiple myeloma and chronic lymphocytic leukemia patients. Representative work includes a $681,270 firm fixed-price definitive contract awarded by the Defense Health Agency in March 2025 for ClonoSEQ FDA-cleared in vitro diagnostic testing services running through March 2030, a $828,750 single-award Blanket Purchase Agreement with the Department of Veterans Affairs Veterans Integrated Service Network 1 spanning July 2022 through June 2027 for ClonoSEQ testing at VA medical facilities across New England (with six task orders totaling $167 thousand in combined potential value), and a $308,400 purchase order from the National Institute of Allergy and Infectious Diseases in November 2022 for COVID-19-funded immunosequencing services.

Customer concentration splits between research and clinical delivery. The National Institute of Allergy and Infectious Diseases leads by award count at 44 awards ($1.4 million combined potential value), followed by the National Cancer Institute at 34 awards ($1 million), while the Defense Health Agency ranks second in potential value at $1.4 million across four awards. The Department of Veterans Affairs Veterans Integrated Service Network 1 anchors the clinical delivery mission with seven awards ($996 thousand) for ongoing ClonoSEQ testing at Boston, West Haven, West Roxbury, and Seattle VA locations. Combined, these five customer agencies account for 86% of recent award volume and 85% of combined potential value, with HHS NIH agencies (NIAID, NCI, NHLBI, and NIH Clinical Center) representing the largest customer concentration by count and the Defense Health Agency and VA split the clinical delivery base between military healthcare and veterans' medical care.

Adaptive holds a single named parent vehicle: Blanket Purchase Agreement 36C24122A0124 with the VA's Veterans Integrated Service Network 1, from which six task orders totaling $167 thousand have been placed. All 118 recent prime awards are full-and-open procurements with no set-aside designation; Adaptive operates entirely outside small business set-asides. All awards are prime contracts; the vendor carries no subcontractor footprint in the federal portfolio.

Activity volume has moderated in recent years, with eight awards in 2022 declining to five in 2023, nine in 2024, five in 2025, and one award (the VISN 1 BPA call) issued in 2026. Three awards totaling $293 thousand in combined potential value reach ultimate completion within the next twenty-four months, presenting a modest recompete window. Service Contract Inventory data covers one SCI-reportable record in FY2022 as a named subcontractor to another prime, with approximately 0.4 FTEs delivered; this represents a minimal SCI footprint and does not characterize Adaptive's full federal services delivery, which is dominated by diagnostic testing and laboratory services falling outside the SCI reporting threshold.